Related Experiment Videos
Cimetidine prophylaxis after renal transplantation
Insights
Prophylactic use of cimetidine in kidney transplant patients significantly reduced gastrointestinal bleeding without negatively impacting rejection episodes or long-term graft survival, offering a safe preventative measure.
Area of Science:
- Nephrology
- Gastroenterology
- Transplantation Medicine
Background:
- Kidney transplant recipients are at risk of gastrointestinal bleeding.
- Prophylactic gastrointestinal bleeding management is crucial in these patients.
Purpose of the Study:
- To evaluate the efficacy and safety of cimetidine for preventing gastrointestinal bleeding in kidney transplant patients.
- To assess the impact of cimetidine on rejection episodes and graft survival.
Main Methods:
- A prospective study comparing 66 kidney transplant patients treated with cimetidine to 66 historical controls.
- Patients received prophylactic cimetidine without antacids.
- Outcomes measured included gastrointestinal bleeding incidence, rejection episodes, and graft survival.
Main Results:
- Cimetidine treatment significantly reduced the incidence of gastrointestinal hemorrhage (P < 0.05).
- No significant increase in rejection episodes was observed.
- Long-term graft survival was not impaired by cimetidine treatment.
Conclusions:
- Cimetidine is an effective prophylactic agent against gastrointestinal bleeding in kidney transplant recipients.
- This treatment does not adversely affect transplant outcomes, including rejection rates and graft survival.
Abstract:
Over an 18 month period 66 consecutive kidney transplant patients at risk of gastrointestinal bleeding were treated prophylactically with the histamine H2-blocker cimetidine, without antacids. The incidence of gastrointestinal bleeding, the number of rejection episodes, and graft survival were compared with those of 66 patients, who had received a transplant in the period immediately preceding the start of the study, and who had never received cimetidine. The incidence of gastrointestinal hemorrhage was significantly reduced in the cimetidine-treated patients (P less than 0.05). In addition, cimetidine treatment neither increased the total number of rejection episodes nor did it impair long-term graft survival.